Company intelligence / Profile preview

Shanghai Kaibao Pharmaceutical

Ownership: Private
Employees: ~1225
Development stage: Other

Overview

Shanghai Kaibao Pharmaceutical has several commercialized products in China, primarily focused on traditional Chinese medicines such as Tanreqing injection for respiratory infections. The company also has a pipeline with clinical-stage assets including dulanermin in Phase 3 for advanced lung cancer, 20(S)-protopanoxadiol in Phase 2 for depressive disorder, and YKRH‑00020 in Phase 1 for productive cough.

Therapeutic areas: PsychiatryOncologyPulmonologyInfectious Diseases
Modalities: Herbal medicineSmall molecule drug
Industry: Biotech

Drug pipeline

8 assets

tanreqing

7 more assets in the full pipeline.

Request access →

Partnerships

dulanermin is co-developed with Shanghai Gebaide Biotechnology Co., Ltd.

Beyond the preview

Go deeper on Shanghai Kaibao Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Kaibao Pharmaceutical.

Explore the full profile